STL Volume 28 Number 6

Explore risankizumab for Psoriatic arthritis: Beyond ACR, it significantly improves enthesitis, dactylitis, and QoL scores like HAQ-DI. Promising in efficacy and safety, with full 208-week study results anticipated for a complete understanding.

Dupilumab: A groundbreaking FDA and Health Canada-approved treatment for Prurigo Nodularis (PN). This innovative therapy targets IL-4 and IL-13 signalling, effectively reducing inflammation, pruritus, and lesions. Its approval marks a paradigm shift in PN management, offering new hope for patients.

Update on Bimekizumab-bkzx for SC injection (Bimzelx®), Clindamycin 1.2%/adapalene 0.15%/benzoyl peroxide 3.1%fixed-dose topical gel (Cabtreo™), Roflumilast cream 0.3% (Zoryve®), Nivolumab for IV use (Opdivo®), Secukinumab for IV use (Cosentyx®)